Investor Presentaiton

Investor presentation Clinical projects in obesity and NASH Phase 1 PYY 1562 analogue GG-co-agonist Tri-agonist 1706 Phase 2 Obesity PYY 1875 analogue Amylin AM833 NASH Semaglutide NASH Semaglutide NASH + Gilead Science I PYY: peptide YY; GG: GLP-1 and glucagon; NASH: nonalcoholic steatohepatitis; GLP-1: glucagon-like peptide-1 ADA 2019 Slide 24 Phase 3 Marketed Semaglutide obesity Saxenda I liraglutide injection Develop new biologics combined with GLP-1 to achieve >20% weight loss Enter NASH by leveraging GLP-1 and other internal assets as well as in-licensing external opportunities novo nordisk

View entire presentation